124 related articles for article (PubMed ID: 36776078)
1. Prescription of transdermal patches in Colombia: A real-world evidence study.
Valladales-Restrepo LF; Gaviria-Mendoza A; Londoño-Serna MJ; Ospina-Cano JA; Giraldo-Giraldo C; Machado-Duque ME; Machado-Alba JE
Int J Risk Saf Med; 2023; 34(4):325-335. PubMed ID: 36776078
[TBL] [Abstract][Full Text] [Related]
2. Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia.
Reinhardt F; Scarmeas N; Karan R; Veldandi UK; Modali S; Duvvuri K; Pathan RK
Curr Alzheimer Res; 2021; 18(4):273-282. PubMed ID: 34279198
[TBL] [Abstract][Full Text] [Related]
3. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Reñé R; Ricart J; Hernández B;
Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
[TBL] [Abstract][Full Text] [Related]
4. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Greenspoon J; Herrmann N; Adam DN
CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
[TBL] [Abstract][Full Text] [Related]
5. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
[TBL] [Abstract][Full Text] [Related]
6. Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia.
Chauhan MK; Sharma PK
Chem Phys Lipids; 2019 Nov; 224():104794. PubMed ID: 31361985
[TBL] [Abstract][Full Text] [Related]
7. A fatal outcome after unintentional overdosing of rivastigmine patches.
Lövborg H; Jönsson AK; Hägg S
Curr Drug Saf; 2012 Feb; 7(1):30-2. PubMed ID: 22663954
[TBL] [Abstract][Full Text] [Related]
8. Study of prescription-indication of tetracyclines in a population in Colombia.
Valladales-Restrepo LF; Constain-Mosquera CA; Álvarez-Amaya V; Machado-Alba JE
Fundam Clin Pharmacol; 2022 Apr; 36(2):390-396. PubMed ID: 34481423
[TBL] [Abstract][Full Text] [Related]
9. Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6.
Simon A; Amaro MI; Healy AM; Cabral LM; de Sousa VP
AAPS PharmSciTech; 2017 Oct; 18(7):2561-2569. PubMed ID: 28224389
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
[TBL] [Abstract][Full Text] [Related]
11. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
12. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
[TBL] [Abstract][Full Text] [Related]
13. Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial.
Schurad B; Koch C; Schug B; Morte A; Vaqué A; De la Torre R; Iniesta M
Curr Alzheimer Res; 2022; 19(7):541-553. PubMed ID: 36017827
[TBL] [Abstract][Full Text] [Related]
14. Appropriateness of ambulatory prescriptions in Taiwan: translating claims data into initiatives.
Ho YF; Hsieh LL; Lu WC; Hu FC; Hale KM; Lee SJ; Lin FJ
Int J Clin Pharm; 2012 Feb; 34(1):72-80. PubMed ID: 22138781
[TBL] [Abstract][Full Text] [Related]
15. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions.
Adler G; Mueller B; Articus K
Int J Clin Pract; 2014 Apr; 68(4):465-70. PubMed ID: 24588972
[TBL] [Abstract][Full Text] [Related]
16. Use of ergotamine: do physicians in Colombia know how to prescribe it?
Machado-Alba JE; Morales-Plaza CD
Neurologia; 2014 Jun; 29(5):280-5. PubMed ID: 24035295
[TBL] [Abstract][Full Text] [Related]
17. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
18. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
19. Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Pai MC; Aref H; Bassil N; Kandiah N; Lee JH; Srinivasan AV; diTommaso S; Yuksel O
Clin Interv Aging; 2015; 10():1779-87. PubMed ID: 26622172
[TBL] [Abstract][Full Text] [Related]
20. Sex-by-formulation interaction in bioequivalence trials with transdermal patches.
González-Rojano E; Marcotegui J; Morales-Alcelay S; Álvarez C; Gordon J; Abad-Santos F; García-Arieta A
Eur J Clin Pharmacol; 2019 Jun; 75(6):801-808. PubMed ID: 30725220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
